Dynamic risk prediction for severe blood cell suppression in nasopharyngeal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, prospective observational study follows adults with nasopharyngeal carcinoma who are about to start systemic therapy. At each treatment cycle, researchers collect routine clinical and lab data to update a risk prediction for severe myelosuppression. The study does not modify treatment; predictions are used for research only to evaluate the model’s accuracy over the course of therapy and for 28 days after the last treatment. The goal is to understand whether the model can reliably identify patients at higher risk of treatment-related blood cell suppression. Enrollment is consecutive at participating centers, with informed consent required.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Voluntary provision of written informed consent.
* Age ≥18 years.
* Histologically confirmed nasopharyngeal carcinoma.
* Patients who, in the judgment of the treating physician, require systemic anticancer treatment.

Exclusion Criteria:

* Presence of other uncontrolled serious diseases, including unstable cardiac disease requiring treatment, poorly controlled diabetes mellitus (fasting blood glucose \>1.5 times the upper limit of normal), psychiatric disorders, or a history of severe allergy.
* Considered unsuitable for participation in the study by the investigator.

Where it's running

• Nanfang Hospital, Southern Medical University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Jian Guan
• Email: 51643930@qq.com
• Phone: +86-13632102247

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Structured swallowing exercises for nasopharyngeal cancer patients

  This trial tests whether a structured swallowing exercise program improves swallowing and quality of life more than conventional swallowing exercises in adults with nasopharyngeal carcinoma.

  Recruiting Universitas Indonesia · Jakarta Pusat, DKI Jakarta · NCT07909538

• Becotatug Vedotin plus PD-1 inhibitor for locally recurrent nasopharyngeal carcinoma

  This study tests whether adding becotatug vedotin to a PD-1 inhibitor helps people with locally recurrent nasopharyngeal cancer.

  Recruiting Phase 2 Eye & ENT Hospital of Fudan University · Shanghai, Shanghai Municipality · NCT07781358

• Dynamic risk-guided EBV-DNA and MRI-based chemotherapy adjustments in nasopharyngeal carcinoma

  This trial tests whether adjusting adjuvant therapy based on changes in EBV DNA and MRI findings after radiotherapy helps improve outcomes for people with nasopharyngeal carcinoma.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07762976

• Immune Sandwich: Induction with Nimotuzumab and Toripalimab Plus Radiotherapy vs Full-Course Immunotherapy for Advanced Nasopharyngeal Cancer

  This trial tests whether a shortened, targeted immunotherapy plan added to chemoradiation can match the full immunotherapy approach for locally advanced nasopharyngeal cancer in adults 18–70.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT07706985

• RAIRI-guided risk-stratified adjuvant therapy after chemoradiotherapy in nasopharyngeal carcinoma

  This real-world study tests whether the RAIRI model can predict who will benefit from adjuvant therapy after chemoradiotherapy for non-metastatic nasopharyngeal carcinoma.

  Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07618078

• RAIRI-guided adjuvant therapy in nasopharyngeal carcinoma

  This trial tests whether using the RAIRI risk model to guide adjuvant therapy after chemoradiotherapy can spare some patients unnecessary treatment in locoregionally advanced nasopharyngeal carcinoma.

  Recruiting Phase 3 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07590024

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.